Therefore, we speculated that the mutation resulted in the aberrant methylation or down-regulation of ESR1 and EDNRB. Our study implied that ESR1 and EDNRB may serve as targets in the creation of anti-tumor drugs. The gene discussed is ESR1; the disease is neoplasm.